Yuhan Corporation to pay $325M to in-license preclinical HER2 candidate
2023-05-31
AACR会议蛋白降解靶向嵌合体
Yuhan Corporation said
Tuesday
that it is paying up to $325 million to fellow South Korean biotech J INTS Bio to license an oral non-small cell lung cancer drug.
The deal is for JIN-A04, a preclinical oral tyrosine kinase inhibitor targeting NSCLC with HER2 exon 20 mutations.
J INTS Bio
said
back in February that preclinical data on the molecule would be presented at the American Association for Cancer Research’s annual meeting in Orlando, saying that the molecule “showed potent efficacy against HER2 Exon20 insertion mutant NSCLC cell lines, and in-vivo mouse models using HER2 Exon20 insertion mutant cell lines significant tumor regression was demonstrated.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。